Xenon Pharmaceuticals (NASDAQ:XENE – Free Report) had its price target raised by Bank of America from $52.00 to $56.00 in a research report sent to investors on Tuesday, Benzinga reports. Bank of America currently has a buy rating on the biopharmaceutical company’s stock. Several other research firms have also recently weighed in on XENE. StockNews.com […]
Xenon Pharmaceuticals (NASDAQ:XENE – Free Report) had its price target hoisted by JPMorgan Chase & Co. from $54.00 to $59.00 in a report published on Tuesday morning, BayStreet.CA reports. The firm currently has an outperform rating on the biopharmaceutical company’s stock. A number of other research firms also recently weighed in on XENE. Stifel Nicolaus […]
Xenon Pharmaceuticals (NASDAQ:XENE – Get Free Report) had its price target hoisted by equities researchers at JPMorgan Chase & Co. from $54.00 to $59.00 in a note issued to investors on Tuesday, BayStreet.CA reports. The firm currently has an “outperform” rating on the biopharmaceutical company’s stock. JPMorgan Chase & Co.‘s price objective points to a […]
Xenon Pharmaceuticals (NASDAQ:XENE – Get Free Report) and Collegium Pharmaceutical (NASDAQ:COLL – Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk and dividends. Risk and Volatility Xenon Pharmaceuticals has a beta […]
Driehaus Capital Management LLC boosted its holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Free Report) by 2.3% in the second quarter, HoldingsChannel.com reports. The firm owned 4,760,853 shares of the biopharmaceutical company’s stock after buying an additional 105,928 shares during the quarter. Xenon Pharmaceuticals comprises about 2.3% of Driehaus Capital Management LLC’s investment portfolio, making […]